Abstract
INVITRO EVALUATION OF GEMCITABINE AND ITS DERIVATIVE (GEMCITABINE-ERLOTINIB) FOR THE TREATMENT OF PANCREATIC CANCER
Dr. Syed Ahmed Hussain*, Shaik Nazma Sultana, Sara Umm E. Hani, Farahanaaz Begum and Juveria Gaffar
ABSTRACT
This research paper examines the cellular impact of Gemcitabine-Erlotinib combination therapy on viability, tubulogenesis, and protein expression levels using MTT assay, Tubulogenesis assay, Indirect Immunofluorescence assay, and Western Blot analysis. The study encompasses four treatment groups: Group 1 (normal), Group 2 (Control cell line), Group 3 (Standard GEMCITABINE), and Group 4 (Gemcitabine-Erlotinib). The results suggest that Gemcitabine-Erlotinib has a significant effect on cell viability and tubulogenesis, while also affecting protein expression levels. These findings emphasize the potential impact of this combination therapy on cellular processes and warrant further investigation.
[Full Text Article] [Download Certificate]WJPLS CITATION
All | Since 2019 | |
Citation | 422 | 322 |
h-index | 9 | 7 |
i10-index | 4 | 2 |
INDEXING
NEWS & UPDATION
BEST PAPER AWARDS
World Journal of Pharmaceutical and life sciences Will give best paper award in every issue in the from of money along with certificate to promote research .
Best Article of current issue
Download Article : Click here